Augmentation therapy comparison in refractory obsessive-compulsive disorder with Aripiprazole vs. Risperidone

A survey about comparison of augmentation therapy in refractory obsessive-compulsive disorder patients; Aripiprazole vs. Risperidone

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2015110424882N1

Enrollment

100

Registered

2016-08-04

Start date

2013-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obsessive-compulsive disorder. Obsessive-compulsive disorder

Interventions

Intervention 1: In a group of patients in addition to SSRI drugs, Aripiprazole, production of sobhan corporation, begun with 2.5 mg and increased gradually to 10 mg, at the end of second week. All of

Treatment - Drugs

In a group of patients in addition to SSRI drugs, Aripiprazole, production of sobhan corporation, begun with 2.5 mg and increased gradually to 10 mg, at the end of second week. All of patients were vi

In other group also, in addition to SSRI drugs, Risperidone, production of sobhan corporation, begun with 1 mg and increased gradually to 2 mg, at the end of the first week. All of patients were visi

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age between 18-60 years;the Yale-Brown obsessive-compulsive scale (Y-BOCS) =16 and suffering from OCD whilst were taken a therapeutic dose of SSRI drugs at least for 12 weeks;negative history of: pregnant or breastfeeding in women; psychotic, bipolar mood, and severe depressive disorders in DSM-IV-TR axis I; any known disorder in DSM-IV-TR axis II like personality disorders or mental retardation; drug and alcohol abuse in the last six months before study; any physical disease impeding the use of Risperidone or Aripiprazole; not psychotherapy during the study. Exclusion criteria: Any acute or severe physical diseases occurring during the study; more than four weeks loss to follow-up; severe side effects during the study; not using contraceptive methods in females.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of symptoms of OCD. Timepoint: Basline and every 4 weeks. Method of measurement: Y_BOCS.	—

Secondary

Measure	Time frame
Unwanted side effects of drugs. Timepoint: Every 4 weeks. Method of measurement: Interview.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Fatemeh Assarian

Kashan University of Medical Sciences

fa_assar@yahoo.com+98 31 5554 9111

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026